News

Upcoming changes to MBS items for Chronic Disease Management

By Toby Vue posted 06-09-2024
1 person recommends this.
The government is introducing changes to Chronic Disease Management (CDM) MBS items, which will come into effect on 1 November 2024 , pending the passing of legislation. These changes involve the consolidation of existing plans and adjustments to referral processes, aiming to simplify and reduce the administrative workload for healthcare providers, like CDEs. Key points The current GP Management Plan (GPMP) and Team Care Arrangement (TCA) will be combined into a new GP Chronic Condition Management (CCM) plan (previously known as CDM Plan). People with an existing GPMP and/or TCA before 1 November 2024 can continue to access services under those ...
0 comments

Your voice matters: shine a light on rural and remote CDEs

By Toby Vue posted 14-06-2024
Be the first person to recommend this.
The Australian Diabetes Educator (ADE) publication is inviting CDEs working in rural and remote areas to contribute to our esteemed publication. This is a unique opportunity to highlight your significant roles in making positive differences in communities where healthcare resources are often limited. We are seeking one-page articles that provide a window into your world. Share your journey, your passion, and the realities of your work with a wider audience. This is your chance to shine a light on what it means to be a CDE in the heart of Australia's diverse landscapes . We are flexible with the content and the following are examples ...
0 comments

ADEA leaders receive prestigious award for helping First Nations students in diabetes education

By Toby Vue posted 09-04-2024
Be the first person to recommend this.
ADEA leaders, including CDEs, are among the recipients of the latest UTS Vice-Chancellor's Academic Support Award. Photo: Supplied ADEA leaders are among the recipients of a University of Technology Sydney (UTS) award for helping First Nations students in diabetes education. On 3 April, 10 health education leaders received the Academic Support Award as part of the UTS Vice-Chancellor's Learning and Teaching Awards. The accolade recognises the recipients' outstanding support of First Nations diabetes students to promote First Nations health outcomes . Congratulations to Professor David Sibbritt, Dr Shannon Lin, Ms Grace Ward, Dr Danielle Manton, ...
0 comments

Reminder: PBS restriction changes to type 2 diabetes medicines

By Toby Vue posted 06-03-2024
Be the first person to recommend this.
On 1 June 2024, changes were made to the PBS restrictions for several type 2 diabetes medicines. These changes include authority requirements and restrictions for GLP-1 RAs, including semaglutide, and were based on a PBAC review and consultation with stakeholders, including relevant consumer and prescriber groups. Changes to PBS authority and restrictions for GLP-1 RAs Starting GLP-1 RA therapy now requires approval via phone or electronic means, rather than streamlined authority. Continued access is via streamlined authority. To receive PBS-subsidised GLP-1 RA therapy, a consumer must be contraindicated, intolerant, or must not have achieved a clinically ...
0 comments

Scholarships available for Aboriginal and Torres Strait Islander students

By Toby Vue posted 25-01-2024
Be the first person to recommend this.
ADEA will be opening the scholarships for Aboriginal and Torres Strait Islander students soon. If you are interested or know someone who is, please have them contact [email protected] for details . To be eligible, students must: identify as Aboriginal and/or Torres Strait Islander be accepted to an ADEA accredited University Graduate Certificate in Diabetes Management Program have an appropriate underlying health profession: Aboriginal and/or Torres Strait Islander Health Practitioner, Medical Practitioner, Registered Nurse, Registered Midwife, Accredited Practising Dietitian, Accredited Exercise Physiologist, Registered Pharmacist, Registered ...
0 comments

Novo Nordisk issues urgent defect alert: insulin cartridge

By Toby Vue posted 19-01-2024
Be the first person to recommend this.
Novo Nordisk has issued an urgent product defect alert affecting the 3mL glass cartridges that contain Actrapid, NovoRapid, NovoMix 30, Mixtard 30/70, and Protaphane . In its letter to healthcare professionals today, Novo Nordisk states that during manufacture, 'circular non-penetrating cracks on the outer surface around 4–6 mm below the ''shoulder'' of the glass cartridge were found'. 'These outer surface cracks do not compromise the integrity of the cartridge,' the statement reads. 'As the integrity of the cartridge remains intact, there is no risk of evaporation or contamination of the product.' Novo Nordisk states that if the cartridge cracks while ...
0 comments

ADEA welcomes new alliance to strengthen gestational diabetes care

By Toby Vue posted 16-01-2024
Be the first person to recommend this.
ADEA has welcomed the alliance between Diabetes Australia (DA) and the Australasian Diabetes in Pregnancy Society (ADIPS) to strengthen the support and advocacy to address the diabetes epidemic. DA, one of ADEA''s unified partners, announced on 15 January that ADIPS had become an Associate Member of DA to 'further strengthen Australian and New Zealand international leadership in clinical practice, research and advocacy for women with diabetes in pregnancy, their families and care providers'. ADEA, DA, and the Australian Diabetes Society will work closely with ADIPS, and this will further strengthen and embed this new alliance within the unified organisations. ...
0 comments

Update to ADEA Code of Conduct and Social Media Policy for Members

By Toby Vue posted 15-12-2023
Be the first person to recommend this.
Dear members: We regularly review and update our governance and policy documents, and the ADEA Board has recently approved updates to the ADEA Member Code of Conduct and the Social Media Policy. Both documents are effective immediately (as of 15 December 2023). Please see the latest versions of both documents: ADEA Code of Conduct ADEA Social Media Policy for Members We will also advise members in our e-newsletter next week and provide reminders in January for those who may miss the advice due to the festive season and holidays.
0 comments

ADEA wins prestigious international award for 'leading-edge' diabetes education

By Toby Vue posted 30-11-2023
Be the first person to recommend this.
An ADEA co-developed education framework for diabetes management and care has received one of the most prized accolades in the world of learning, talent, and skills development. The microcredential and digital badging framework for diabetes education that ADEA developed with educonomy, a consultancy firm that works with peak industry bodies and education providers to elevate learning experiences, was awarded LearnX's 2023 Platinum Certificate for Best Learning Model — Future Learning. The award, the highest at seven stars, focuses on a learning project an enterprise implemented to create a future model and pathway for enterprise education to drive and support ...
0 comments

Champions of Diabetes Care: CDEs of the Year on World Diabetes Day 2023

By Toby Vue posted 14-11-2023
Be the first person to recommend this.
On World Diabetes Day 2023, let’s come together to honour the inspiring work of our members who are transforming the lives of people living with diabetes. Through their dedication and expertise, CDEs are making a significant impact in improving diabetes education and care. Join us as we celebrate their achievements and reaffirm our commitment to creating a future where diabetes prevention, management, and support are available to all. Read all about it on the ADEA website .
0 comments

Reminder to clients about semaglutide products amid crackdown on counterfeit versions

By Toby Vue posted 14-11-2023
Be the first person to recommend this.
ADEA reminds its members to remind their clients that semaglutide products should be sourced from only trusted authorities amid the continued reports about counterfeit products putting consumers' health at risk. Recent media reports also state that regulators across the world have issued warnings in their crackdown of fake semaglutide, also known as Ozempic, being sold online. The Therapeutic Goods Administration (TGA) issued a warning in May after it detected counterfeit semaglutide being illegally imported into Australia. 'These results serve as a warning to consumers to avoid buying semaglutide products from unverified online sellers as they may not ...
0 comments

Diabetes Connekt receives sleek makeover on World Diabetes Day

By Toby Vue posted 14-11-2023
Be the first person to recommend this.
ADEA is excited to launch a revamped Diabetes Connekt to coincide with World Diabetes Day today . The all-in-one digital platform for health professionals in diabetes education and care has undergone a sleek makeover to enhance user experience. The redesigned platform, which also marks one year since it went live, aligns with World Diabetes Day's current theme: access to care. The changes include a visual refresh of the homepage, including a cleaner organisation of key information, such as the latest diabetes news, announcements, events, and community highlights. This ensures ADEA members, CDEs, diabetes educators, and other health professionals have ...
0 comments

ADEA and unified partners launch new research funding campaign as part of World Diabetes Day

By Toby Vue posted 10-11-2023
Be the first person to recommend this.
This World Diabetes Day on 14 November , ADEA and its unified partners, Diabetes Australia and the Australian Diabetes Society (ADS), are launching the Diabetes Research Changes Lives campaign to highlight the impact of research transforming the lives of people living with diabetes and call for more funding for diabetes research. To change the trajectory of the diabetes epidemic, research must be at the forefront of our response. We have world-class researchers, undertaking world-class research, but this can’t be sustained if funding continues to decline. To read more about the campaign and how you can support it, the three organisations have published ...
0 comments

GlucaGen HypoKit shortage extended by one month

By Toby Vue posted 03-10-2023
Be the first person to recommend this.
The shortage of the glucagon product GlucaGen HypoKit has been extended by one month after manufacturing delays were expected to last until September 30. Supplier Novo Nordisk notified the Therapeutic Goods Administration (TGA) about the latest update and in a statement on 28 September, the TGA said that while the current shortage is expected to end by 31 October 2023, this date may change. In August, the TGA approved several overseas-registered glucagon products due to the critical shortage of GlucaGen HypoKit. The TGA encourages people to check its medicine shortage reports database for updates about the supply of the product. Related: TGA ...
0 comments

New Ozempic advice issued as demand 'accelerated in recent months'

By Toby Vue posted 22-09-2023
Be the first person to recommend this.
Supplies of Ozempic will be limited for the rest of 2023 and during 2024, prompting the TGA to urge prescribers to avoid starting new people on the medicine 'unless there are no suitable alternatives or there is a compelling clinical reason to do so'. The latest advice comes after supplier Novo Nordisk notified the TGA and the Ozempic Medicine Shortage Action Group that demand 'had accelerated in recent months, particularly for the low-dose (0.25/0.5 mg) version'. 'This additional demand is caused mainly by a rapid increase in prescribing for off-label use,' the TGA said on 21 September. 'When deciding whether to continue treatment, consult the appropriate ...
0 comments

The ADEA member survey results can now be accessed on the LMS!

By Jeffrey Fan posted 20-09-2023
Be the first person to recommend this.
ADEA conducted the Member Survey for 2023. The survey results revealed that the majority of ADEA members are satisfied with their membership and appreciate the value and education resources ADEA produces. Furthermore, the survey highlighted a few membership areas for improvement, which we will continue working to address. For details of the findings, please refer to the 2023 Membership Survey Data PDF document available on the LMS, you can also access the PDF by clicking on the Membership and branches button on the LMS site menu.
0 comments

Fiasp Penfill to be on PBS from October after ADEA advocacy

By Toby Vue posted 18-09-2023
Be the first person to recommend this.
The federal government is listing Fiasp Penfill on the Pharmaceutical Benefits Scheme (PBS) from 1 October for people affected by the removal of Fiasp vial and Fiasp FlexTouch. In a statement on 18 September, the government said it had negotiated with Novo Nordisk to list Fiasp Penfill and that the listing was welcomed news for the more than 15,000 Australians living with diabetes. It comes after the ADEA, other leading advocacy organisations, and people living with diabetes provided feedback about the removal of the vial and FlexTouch products from the PBS . Supplier Novo Nordisk announced the removal of those products from the PBS from 1 April for ...
0 comments

'Delivering the highest standard of diabetes education': CDEs of the year announced

By Toby Vue posted 28-08-2023
1 person recommends this.
University course director Dr Shannon Lin has been announced as the 2023 Jan Baldwin National CDE of the Year. ADEA made the announcement at the Australasian Diabetes Congress in Adelaide on 24 August following calls for nominations. Dr Lin was also named NSW CDE of the Year. Dr Shannon Lin (second from left) received the 2023 Jan Baldwin National CDE of the Year award at the Australasian Diabetes Congress on 24 August. Pictured with her are Eli Lilly Australia and New Zealand’s General Manager Tori Brown, Jan Baldwin’s husband Bob Walsh, and ADEA President Amanda Bartlett. Photo: Jeff Fan CDEs of the year for the other states and ...
1 comment

Overseas glucagon products approved due to GlucaGen HypoKit shortage

By Toby Vue posted 08-08-2023
Be the first person to recommend this.
Several overseas-registered glucagon products have been approved by the Therapeutic Goods Administration (TGA) due to a critical shortage of the emergency glucagon product GlucaGen HypoKit . Supplier Novo Nordisk Pharmaceuticals recently notified the TGA that the shortage, due to a 'shortfall in the release and supply of pre-filled syringes from an external vendor' resulting in supply constraints, was expected to last until 30 September. The overseas glucagon products, which are listed on the TGA’s approvals database , were approved under section 19A of the Therapeutic Goods Act 1989 . In a recent statement, the TGA said priority should be given ...
0 comments

'CDEs are very much the solution': Help inform ADEA's diabetes inquiry submission

By Toby Vue posted 08-08-2023
Be the first person to recommend this.
CDE Media Champions are ramping up the campaign about the importance of CDEs in diabetes care and education following this year’s National Diabetes Week , which focused on having the biggest conversation about the condition's impact and on advocating for improvement. It comes as ADEA and its unified partners encourage all stakeholders to contribute their insights to the organisations’ submission to a parliamentary inquiry into diabetes . To help encourage discussions and ADEA members' contributions to the submission, the following CDE Media Champions spoke with ADEA about issues related to the profession and its workforce: Diana Ly, accredited ...
0 comments